TREM2, Polyclonal Antibody

Anti -TREM2, CT (Triggering Receptor Expressed On Myeloid Cells 2, TREM-2, Triggering Receptor Expressed on Monocytes 2)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 6; NC_000006.11 (41126244..41130924, complement). Location: 6p21.1

Polyclonal

Goat

Recognizes human TREM2.

Affinity Purified
Purified by immunoaffinity chromatography.

Supplied as a liquid in TBS, pH 7.3, 0.5% BSA, 0.02% sodium azide.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-TREM2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

TREM-2 (Triggering Receptor Expressed by Myeloid cells) is an Ig superfamily cell surface receptor that activates a number of myeloid cell types. It is a member of a small gene family located on human chromosome 6p21 and mouse chromosome 17 in a region linked to the MHC. A single human TREM-2 gene has been described, however, two closely related orthologs were reported in mouse. The proteins differ by only 3aa and were designated TREM-2a and TREM-2b. TREM-2 is type I transmembrane protein consisting of a single extracellular immunoglobulin (V-like) domain, a transmembrane domain with a positively charged lysine residue, and a short cytoplasmic tail. It associates with the signal adapter protein, DAP12, for signaling and function. DAP12 has a cytoplasmic ITAM that is phosphorylated upon ligand binding leading to the subsequent activation of cytoplasmic tyrosine kinases. TREM-2 is expressed by immature monocyte-derived dendritic cells (DC), and expression is down-regulated upon activation of DC by microbial products and costimulatory signals. Ligation of TREM-2 on immature DC with anti-TREM-2 antibodies results in partial DC activation and the up-regulation of CCR7 and some co-stimulatory molecules. A role for TREM-2 in the functioning of osteoclasts and microglia is suggested by the discovery that homozygous loss-of-function mutations in either TREM-2 or DAP12 result in Nasu-Hakola disease characterized by a combination of presenile demetia and bone cysts. In vitro studies indicate that the differentiation of myeloid precursors into osteoclasts is dramatically impaired in TREM-2 deficient individuals.

Antibodies; Abs to Receptors

ELISA (EL/EIA), Immunohistochemistry (IHC)

Suitable for use in ELISA and Immunohistochemistry.
Dilution: ELISA: 1:32,000
Immunohistochemistry (Formalin fixed paraffin embedded): 2.5ug/ml

25,447 Da[Similar Products]

triggering receptor expressed on myeloid cells 2

triggering receptor expressed on myeloid cells 2; triggering receptor expressed on monocytes 2; triggering receptor expressed on myeloid cells 2a

Triggering receptor expressed on myeloid cells 2

TREM-2  [Similar Products]

TREM2_HUMAN

This gene encodes a membrane protein that forms a receptor signaling complex with the TYRO protein tyrosine kinase binding protein. The encoded protein functions in immune response and may be involved in chronic inflammation by triggering the production of constitutive inflammatory cytokines. Defects in this gene are a cause of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Nov 2012]

Function: May have a role in chronic inflammations and may stimulate production of constitutive rather than inflammatory chemokines and cytokines. Forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. Ref.1

Subunit structure: Interacts with TYROBP/DAP12

By similarity.

Subcellular location: Isoform 1: Cell membrane; Single-pass type I membrane protein

Potential. Isoform 2: Secreted

Potential. Isoform 3: Secreted

Potential.

Tissue specificity: Expressed on macrophages and dendritic cells but not on granulocytes or monocytes. In the CNS strongest expression seen in the basal ganglia, corpus callosum, medulla oblongata and spinal cord. Ref.1 Ref.4

Involvement in disease: Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) [MIM:221770]: Recessively inherited disease characterized by a combination of psychotic symptoms rapidly progressing to presenile dementia and bone cysts restricted to wrists and ankles. PLOSL has a global distribution, although most of the patients have been diagnosed in Finland and Japan, with an estimated population prevalence of 2x10(-6) in the Finns.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.4

Sequence similarities: Contains 1 Ig-like V-type (immunoglobulin-like) domain.

Sequence caution: The sequence BAB78736.1 differs from that shown. Reason: Erroneous initiation.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.